GSK prevails in Paxil preemption case as Supreme Court refuses review

GSK prevailed in its Paxil preemption case as the Supreme Court refused to weigh an appeals court's decision to toss a $3 million jury verdict. A lower court had awarded damages to the widow of a man who committed suicide while taking a generic copy of the GSK antidepressant.